SCHEMBL24190232

SCHEMBL24190232

COC(=O)c1nc2c(Cl)ccc(Cl)c2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.40
KMT2A Q03164 3/20 0.40
NR4A2 P43354 3/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.39
RHEB Q15382 1/20 0.38
ALPL P05186 1/20 0.37
ALDH1A1 P00352 1/20 0.36
NOTUM Q6P988 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
KDM4E B2RXH2 2/20 0.35
PKM P14618 1/20 0.35
RCE1 Q9Y256 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758835 0.80 ALOX15 (0.42) SMN1; SMN2ALPLLMNATSHRCYP1A2
SCHEMBL23824446 0.80 KDM4E (0.41) HSD17B10RHEBALDH1A1LMNATSHR
SCHEMBL24113223 0.78 NR4A2 (0.48) F2KMT2ANR4A2HPGDMAPT
SCHEMBL7704923 0.78 MAOB (0.50) F2KMT2ANR4A2HPGDMAPT
SCHEMBL24019965 0.77 ALPL (0.39) KMT2AALPLALDH1A1LMNATSHR
SCHEMBL15808262 0.74 PDE4A (0.43) NR4A2MAPTSMN1; SMN2ALDH1A1GAA
SCHEMBL25812244 0.73 LMNA (0.49) KMT2AHPGDMAPTSMN1; SMN2ALDH1A1
SCHEMBL24020387 0.72 HRH4 (0.56) F2KMT2ANR4A2HSD17B10RHEB
SCHEMBL25758898 0.72 PDE4A (0.43) HPGDMAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL11163748 0.68 NPSR1 (0.41) F2KMT2ANR4A2HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 CN disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 EP disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed
US-20220009903-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 F2 4449/4885KMT2A 4121/4885NR4A2 3319/4885
US-20220009903-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 F2 4449/4885KMT2A 4121/4885NR4A2 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.